Although no mutually exclusive mutation pairs were identified, prior studies in RCC have reported recurrent alterations in TP53 and PTEN, with chRCC exhibiting particularly high mutation rates in both genes [5,19,20,31]. This evidence concerns the gene TP53 and renal cell carcinoma.